Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Liabilities and Shareholders Equity (2022 - 2026)

HeartSciences' Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $7.6 million for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 32.45% year-over-year to $7.6 million; the TTM value through Jan 2026 reached $24.2 million, down 22.34%, while the annual FY2025 figure was $4.2 million, 55.56% down from the prior year.
  • Liabilities and Shareholders Equity reached $7.6 million in Q1 2026 per HSCS's latest filing, up from $6.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $10.8 million in Q1 2024 to a low of $2.1 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $5.6 million, with a median of $5.6 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 228.38% in 2024, then crashed 55.56% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $4.8 million in 2022, then plummeted by 50.36% to $2.4 million in 2023, then surged by 228.38% to $7.8 million in 2024, then decreased by 22.9% to $6.0 million in 2025, then grew by 25.99% to $7.6 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Liabilities and Shareholders Equity are $7.6 million (Q1 2026), $6.0 million (Q4 2025), and $6.4 million (Q3 2025).